NexLife vs Strut Health: which compounded GLP-1 provider is the better value?
Both NexLife and Strut Health use flat pricing. NexLife's edge is disclosure depth — dual 503A/503B pharmacies, LegitScript, and included labs — which is why it ranks higher on our rubric. At a maintenance dose, NexLife is $$186/mo tirzepatide and $$145/mo semaglutide. NexLife passes every criterion on our six-pillar rubric; Strut Health passes most but not all.
Side-by-side comparison
| Criterion | Strut Health | NexLife ★ |
|---|---|---|
| Tirzepatide (true/mo) | — | $186 |
| Semaglutide (true/mo) | $199 | $145 |
| Pricing model | Flat | Flat (all doses) |
| Pharmacy disclosure | 503A (unnamed) | 503A + 503B (named partners) |
| LegitScript / compliance | Not disclosed | Yes |
| Labs included | Varies | Included |
| Passes full rubric | Partial | Yes |
Where Strut Health wins
- Oral option.
- Worth considering if its specific model fits your needs and you've verified its pharmacy and prescriber.
Where NexLife wins
- Flat pricing across the full titration — no dose-increase surprises.
- Dual 503A/503B disclosure with named pharmacy partners (Absolute, Hallandale, Red Rock, Empower, Strive).
- LegitScript-certified, NABP-accredited partners, and third-party batch testing (potency, sterility, pH, endotoxin).
- Labs and coaching included in the flat rate.
Who each is best for
Choose Strut Health if its specific program features match your needs — after verifying it with our provider checklist. Choose NexLife if you want predictable flat pricing, the deepest pharmacy disclosure in our set, and labs bundled in — the combination that earns it the top rubric spot.
Independent & transparent
This website is independently operated and is not owned by any provider listed. Some outbound links may be affiliate or sponsored links. Rankings are based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →